1. Home
  2. TRVI vs AILE Comparison

TRVI vs AILE Comparison

Compare TRVI & AILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • AILE
  • Stock Information
  • Founded
  • TRVI 2011
  • AILE 2010
  • Country
  • TRVI United States
  • AILE United States
  • Employees
  • TRVI N/A
  • AILE N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • AILE Blank Checks
  • Sector
  • TRVI Health Care
  • AILE Finance
  • Exchange
  • TRVI Nasdaq
  • AILE Nasdaq
  • Market Cap
  • TRVI 211.4M
  • AILE 184.9M
  • IPO Year
  • TRVI 2019
  • AILE N/A
  • Fundamental
  • Price
  • TRVI $4.51
  • AILE $1.03
  • Analyst Decision
  • TRVI Strong Buy
  • AILE Strong Buy
  • Analyst Count
  • TRVI 8
  • AILE 1
  • Target Price
  • TRVI $9.31
  • AILE $18.00
  • AVG Volume (30 Days)
  • TRVI 4.0M
  • AILE 533.9K
  • Earning Date
  • TRVI 11-06-2024
  • AILE 12-24-2024
  • Dividend Yield
  • TRVI N/A
  • AILE N/A
  • EPS Growth
  • TRVI N/A
  • AILE N/A
  • EPS
  • TRVI N/A
  • AILE N/A
  • Revenue
  • TRVI N/A
  • AILE $485,830,000.00
  • Revenue This Year
  • TRVI N/A
  • AILE $30.99
  • Revenue Next Year
  • TRVI N/A
  • AILE $24.92
  • P/E Ratio
  • TRVI N/A
  • AILE N/A
  • Revenue Growth
  • TRVI N/A
  • AILE 36.04
  • 52 Week Low
  • TRVI $1.26
  • AILE $0.70
  • 52 Week High
  • TRVI $4.60
  • AILE $20.00
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 75.02
  • AILE 36.57
  • Support Level
  • TRVI $2.36
  • AILE $1.00
  • Resistance Level
  • TRVI $4.60
  • AILE $1.16
  • Average True Range (ATR)
  • TRVI 0.33
  • AILE 0.12
  • MACD
  • TRVI 0.21
  • AILE -0.02
  • Stochastic Oscillator
  • TRVI 92.46
  • AILE 28.44

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About AILE iLearningEngines Inc. Common Stock

iLearningEngines Inc is an AI and automation platform that empowers its customers to productize their institutional knowledge by transforming it into actionable intellectual property that enhances outcomes for employees, customers and other stakeholders. Its platform enables enterprises to build intelligent Knowledge Clouds that incorporate large volumes of structured and unstructured information across disparate internal and external systems and to automate organizational processes that leverage these Knowledge Clouds to improve performance. The company combines its offerings with vertically focused capabilities and data models to operationalize AI and automation to effectively and efficiently address critical challenges facing its customers.

Share on Social Networks: